The Novel BACE Inhibitor MK-8931 Dramatically Lowers CSF Aβ Peptides in Healthy Subjects: Results from a Rising Single Dose Study

被引：0
|
作者：
Forman, Mark
Tseng, Jack
Palcza, John
Leempoels, Jos [1 ]
Ramael, Steven [1 ]
Krishna, Gopal
Ma, Lei
Wagner, John
Troyer, Matthew
机构：
[1] SGS Life Sci Serv, Antwerp, Belgium
来源：
NEUROLOGY | 2012年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
PL02004
引用
收藏
页数：3
相关论文
共 33 条
  • [1] Pharmacokinetics and Pharmacodynamics of the BACE1 Inhibitor Verubecestat (MK-8931) in Healthy Japanese Adults: A Randomized, Placebo-Controlled Study
    Min, K. Chris
    Dockendorf, Marissa F.
    Palcza, John
    Tseng, Jack
    Ma, Lei
    Stone, Julie A.
    Kleijn, Huub J.
    Hodsman, Peter
    Masuo, Kazuko
    Tanen, Michael
    Troyer, Matthew D.
    van Vugt, Marianne
    Forman, Mark S.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 (05) : 1234 - 1243
  • [2] Pharmacokinetics of Cenobamate (YKP3089): Results From Single and Multiple Oral Rising-Dose Studies in Healthy Subjects
    Vernillet, Laurent
    Kamin, Marc
    [J]. NEUROLOGY, 2018, 90
  • [3] Safety, tolerability, and pharmacokinetics of etamicastat, a novel dopamine-β-hydroxylase inhibitor, in a rising multiple-dose study in young healthy subjects
    Nunes T.
    Rocha J.F.
    Vaz-Da-Silva M.
    Igreja B.
    Wright L.C.
    Falcão A.
    Almeida L.
    Soares-Da-Silva P.
    [J]. Drugs in R & D, 2010, 10 (4) : 225 - 242
  • [4] AZD3293 A NOVEL BACE1 INHIBITOR: SAFETY, TOLERABILITY, AND EFFECTS ON PLASMA AND CSF Aβ PEPTIDES FOLLOWING SINGLE- AND MULTIPLE-DOSE ADMINISTRATION
    Alexander, Robert
    Budd, S.
    Russell, M.
    Kugler, A.
    Cebers, G.
    Ye, N.
    Olsson, T.
    Burdette, D.
    Maltby, J.
    Paraskos, J.
    Elsby, K.
    Han, D.
    Goldwater, R.
    Ereshefsky, L.
    [J]. NEUROBIOLOGY OF AGING, 2014, 35 : S2 - S2
  • [5] PHARMACOKINETICS OF CENOBAMATE (YKP3089): RESULTS FROM SINGLE AND MULTIPLE ORAL RISING-DOSE STUDIES IN HEALTHY SUBJECTS.
    Vernillet, L.
    Kamin, M.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 : S54 - S54
  • [6] Single-rising-dose pharmacokinetics, pharmacodynamics, and tolerability of alogliptin benzoate (SYR-322), a novel, dipeptidyl peptidase-IV inhibitor, in healthy male subjects
    Christopher, R.
    Covington, P.
    Davenport, M.
    Fleck, R.
    Mekki, Q.
    Wann, E.
    Karim, A.
    [J]. DIABETOLOGIA, 2007, 50 : S367 - S368
  • [7] A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single-Dose and Multiple-Rising-Dose Study of the BTK Inhibitor TAK-020 in Healthy Subjects
    Esfandiari, Ehsanollah
    Chen, Mary
    Smithson, Glennda
    Blair, Derek
    Faessel, Helene
    Wagner, John
    Mclean, Lachy
    Fedyk, Eric R.
    [J]. CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2021, 14 (03): : 820 - 828
  • [8] Pharmacokinetic Similarity of ABP 710 Relative to Infliximab: Results from a Randomized, Single-Blind, Single-Dose, Parallel Group Study in Healthy Subjects
    Kaur, Primal
    Chow, Vincent
    Zhang, Nan
    Krishnan, Eswar
    [J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [9] Pharmacokinetic Equivalence of ABP 501 Relative to Adalimumab: Results from a Randomized, Single-Blind, Single-Dose, Parallel Group Study in Healthy Subjects.
    Kaur, Primal P.
    Chow, Vincent
    Zhang, Nan
    Moxness, Mike
    Markus, Richard
    [J]. ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S661 - S662
  • [10] A Phase I, Single-Ascending-Dose Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DS-2969b, a Novel GyrB Inhibitor
    Dennie, Justin
    Vandell, Alexander G.
    Inoue, Satoshi
    Gajee, Roohi
    Pav, Joseph
    Zhang, George
    Zamora, Cynthia
    Masuda, Nobuhisa
    Uchiyama, Minoru
    Yamada, Makiko
    Senaldi, Giorgio
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 58 (12): : 1557 - 1565
1234